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Abstract
Green-plant thylakoids increase satiety by affecting appetite hormones such as ghrelin, cholecystokinin (CCK) and
glucagon-like peptide-1 (GLP-1). The objective of this study was to investigate if thylakoids also affect
gastrointestinal (GI) passage and microbial composition. To analyse the effects on GI passage, 16 rats were gavage-
fed a control or thylakoid-supplemented high-fat diet (HFD) 30 min before receiving Evans blue. Another 16 rats
were fed a control HFD or thylakoid HFD for two weeks prior to the intragastric challenge with Evans blue. The
amount of Evans blue in the stomach and the distance of migration in the intestines after 30 min were used as a
measurement of gastric emptying and intestinal transit. These were reduced by thylakoid supplementation in the
acute study, and however not significantly also after the two-week diet study.
The second aim of the study was to investigate if thylakoid-supplementation affects the gut microbiota and amount of
faecal fat in healthy human volunteers (n = 34) receiving thylakoid or placebo treatments for three months. Microbiota
was analysed using 16S rRNA gene sequencing and qPCR, and faecal fat was extracted by dichloromethane. The total
bacteria, and specifically the Bacteriodes fragilis group, were increased by thylakoid treatment versus placebo, while
thylakoids did not cause steatorrhea. Dietary supplementation with thylakoids thus affects satiety both via appetite
hormones and GI fullness, and affects the microbial composition without causing GI adverse effects such as
steatorrhea. This suggests thylakoids as a novel agent in prevention and treatment of obesity.
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Background
Satiety is regulated by several physiological and psycho-
logical factors, including the taste and composition of
the meal, gastric distension and emptying rate, transit
time through the gastrointestinal (GI)-tract, digestion
and absorption of nutrients, secretion of satiety hor-
mones and suppression of hunger hormones, as well as
the awareness of previous mealtime [1]. Recent strategies
in the fight against obesity, overweight and metabolic
diseases are diet and exercise recommendations,
pharmacological treatments, and irreversible surgeries
such as gastric bypass. Since obesity increases the risk
for cardiovascular disease, non-alcoholic fatty-liver dis-
ease, diabetes, various cancers, arthritis and cognitive
impairment [2], the economical cost of medical treat-
ments are increasing [3, 4]. Today, the pharmaceutical
agents present for treating obesity include drugs affect-
ing or mimicking appetite regulating hormones, diges-
tion and/or absorption of nutrients, or rewarding and
food-seeking areas of the brain. The therapeutic agent
Orlistat works by inhibiting lipolysis, with the result that
about 30 % of triglycerides in the food are not being
digested and absorbed, hence less energy is absorbed.
The result is approximately 10 % body weight loss in
one year, but with medium to severe gastrointestinal
symptoms, such as steatorrhea [5].
* Correspondence: Caroline.Montelius@telia.com
1Department of Experimental Medical Science, Appetite Regulation Unit,
BMC B11, Lund University, Sölvegatan 19, SE-221 84 Lund, Sweden
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Stenblom et al. Nutrition & Metabolism  (2016) 13:67 
DOI 10.1186/s12986-016-0128-4
Thylakoids are part of the chloroplast in all green
leaves, as they are the sites for the photosynthesis.
Thylakoids consist of various membrane-bound pro-
teins, galactolipids, phospholipids and antioxidants such
as chlorophyll, carotenoids, zeaxanthin and lutein [6].
Thylakoids extracted from spinach have previously been
found to prolong lipolysis [7], decrease glucose-uptake
over the intestinal wall and to create an extra temporary
layer covering the mucosal side of the intestine [8]. In
animal studies, thylakoid supplementation results in a
decreased amount of body fat [9] and decreased food in-
take [10, 11]. In human intervention studies, thylakoids
have been shown to promote satiety by affecting subject-
ive fullness, hunger and urge for specific foods, as well
as to enhance the release of the appetite-suppressant
hormones cholecystokinin (CCK), glucagon-like peptide-
1 (GLP-1) and leptin, and to suppress the hunger-
hormone ghrelin [12–16]. Effects on glucose and insulin
homeostasis after standardised meals, as well as in the
fasting condition, have also been reported [12, 13, 15].
Moreover, thylakoid supplementation promotes body
weight loss in humans; 6.3 % in three months [12].
Alterations of the microbial composition in the gut
have in recent years been identified as important for de-
velopment of various disorders, including obesity [17].
Investigating physiological effects of the various bacterial
groups has been proposed to be more important than
the precise taxonomical composition. The known func-
tions of the most occurring bacteria in the gut can so far
be divided in the metabolic (affecting digestion), the pro-
tective (protecting against pathogens) and the trophic
(affecting epithelial cell proliferation and differentiation)
[17]. The bacterial groups affecting metabolism work
through enzymatic reactions cleaving glycoside linkages
present in polysaccharides and dietary fibres, resulting in
oligosaccharides and monosaccharides which are then
fermented into short-chain fatty acids (SCFA), such as
acetate, propionate and butyrate [17]. The SCFA are
then absorbed into the bloodstream, and utilized as sub-
strates for gluconeogenesis and lipogenesis [17]. Another
function of the SCFAs is to act as ligand to free fatty
acid receptors, which have been found to affect satiety
and insulin sensitivity [2]. The metabolic effect of this
activation is induced expression of the satiety hormones
peptide tyrosine-tyrosine (PYY) and GLP-1, secreted
from intestinal enterocytes, and leptin secreted from adi-
pose tissue [2]. The result would hypothetically be an in-
creased satiety. Gut microbiota is also involved in
increasing the bioavailability of antioxidants in the food
consumed. This is due to the bacteria hydrolysing esters,
glycosides and polymers in the food matrix, thereby re-
leasing polyphenolic compounds [18].
The aim of the present study was to investigate how
thylakoid supplementation affects gastric emptying,
intestinal transit and plasma concentrations of CCK, using
two rat models; one measuring the immediate effects of a
thylakoid high-fat diet by gavage, and one measuring the ef-
fects after two-weeks of thylakoid supplementation in the
diet. The second aim was to measure the changes in micro-
bial composition in faeces, as well as the amount of faecal




The experiments on gastric emptying and intestinal
transit were performed on Sprague-Dawley rats. The rats
were bred (at the animal facility at the department of
Biology, Lund University, Sweden) and kept under spe-
cific pathogen-free conditions with a controlled environ-
ment (21 ± 2 °C, 50 ± 10 % relative humidity, a 12 h light
– 12 h dark cycle). At 6w of age rats were placed in indi-
vidual cages with ad libitum access to a standard rat
chow-diet (R36, Lantmännen, Sweden) to be acclima-
tised for one week before the experiments started. In
total 30 rats were used, divided between two experi-
ments; one acute study (14 rats) and one two-week
treatment study (16 rats). During both studies a HFD
(46 % fat, 18 % protein and 36 % carbohydrates) pro-
duced by Research Diets Inc. (NJ, USA) was used; one
control and one containing 0.33 g thylakoids/gram feed
(Appethyl, Greenleaf Medical, Stockholm, Sweden). The
control-HFD and thylakoid-HFD were matched for cal-
oric and nutritional content. In the acute study, 1.3 g of
the control-HFD or thylakoid-HFD was given by gavage,
while during the two-week experiment rats had ad
libitum access to their respective feed. The studies were
approved by the Lund University Ethical Review Com-
mittee for Animal Experiments (no. M107-13) and were
conducted according to the European Communities reg-
ulations concerning protection of experimental animals.
Acute study; HFD via gavage
In the acute study, 1.3 g of control HFD or thylakoid HFD
were homogenised with 4 ml drinking water to obtain a
slurry. The rats were lightly anaesthetized with fluothane,
and 2.5 mL of the HFD-slurry was fed via a stomach tube
(control HFD n = 6, and thylakoid HFD n = 8). The thyla-
koid fed rats received in total 0.4 g thylakoids in the
2.5 mL slurry. After 30 min, the rats were again lightly
anaesthetized with fluothane and given an intragastric
bolus dose of 0.25 mL/100 g body weight of 25 mg/mL
Evans blue solution containing 1 % methylcellulose to
obtain a semi-liquid solution. Sixty minutes after the
HFD bolus feeding (30 min after Evans blue), the rats
were deeply anaesthetized with fluothane before a
laparotomy was performed. Blood was collected from
the heart into EDTA tubes, and the rats were sacrificed
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by exsanguination. Blood samples were centrifuged at
3000 × g for 10 min at 4 °C and the plasma was col-
lected and stored in -80 °C until analysed. The stomach
and intestine were then removed, and the intestine
clamped with two sutures beneath the pylorus to pre-
vent leakage of the Evans blue solution. The small in-
testine was separated from the stomach, by cutting
between the strings, and also cut just before the cea-
cum. The total length of the small intestine, as well as
the migration of Evans blue, was measured. The small
intestine was then divided into five equally long
segments using bulldog clamps. Both the intestinal
segments and the stomach were flushed with 10 mL of
the flush solution (0.1 M NaOH + 6 mmol/L NAC)
each, cut open and placed in 15 mL tubes (50 mL for
the stomach). Tubes were shaken vigorously for 60 s
and incubated in room temperature for 60 min.
Two-week ad libitum food intake
In the two-week treatment study, rats were divided into
two groups; one receiving ad libitum access to thylakoid
HFD (n = 8) and one receiving ad libitum access to con-
trol HFD (n = 8) for 2 weeks. On the last day, the rats
were lightly anaesthetized with fluothane and an intra-
gastric bolus dose of Evans blue was given by gavage.
Thirty minutes later the rats were deeply anaesthetized
and the same procedure as described for the acute study
was performed.
Analyses of gastric emptying and intestinal transit
Intestinal and stomach samples were centrifuged at 3000
× g for 30 min at 4 °C, after which 1 mL of each sample
was transferred into Eppendorf tubes and centrifuged at
16 000 × g for 60 min at 4 °C. 100 μL of each sample
was finally loaded onto a 96-well plate and absorbance
was read at wavelength 565 nm (A565). The percentages
of gastric emptying and Evans migration were calculated
using equations 1 and 2 [19].
Equation 1. The percentage of gastric emptying was
calculated by the formula:
ΣA565 intestine 1−5ð Þ
Σ565 stomach þ intestine 1−5ð Þ
 
 100
Equation 2. The percentage of Evans migration was
calculated by the formula:
length of migrated EVANS cmð Þ




Faecal samples were collected from 34 overweight
women (n = 18 in the thylakoid group, n = 16 in the con-
trol group) who had been enrolled in a 12-week diet and
treatment intervention study previously described [12].
A blueberry drink, with or without thylakoid supplemen-
tation, was ingested every morning for 12 weeks. The
blueberry drink contained 50 mL blueberry soup
(Ekströms original, Procordia Food AB, Eslöv, Sweden)
and 2.8 g rapeseed oil (Zeta, Di Luca & Di Luca AB,
Stockholm, Sweden). In the thylakoid blueberry drink
5 g Appethyl (Greenleaf Medical, Stockholm, Sweden)
was added. The caloric content was 209 kJ/50 kcal in
the thylakoid drink and 188 kJ/45 kcal in the control
drink. Exclusion criteria were diabetes, food allergies and
intolerance, irritable bowel syndrome, recent use of anti-
biotics (within six months from inclusion), as well as be-
ing a vegetarian, smoker, pregnant or being on any
weight-loss diet for the last three months.
During the 12-week intervention period subjects were
instructed to consume three meals per day, and no
snacks between meals, as well as to carry out 30 min of
low-to-medium intense exercise every day. During the
12 week intervention all subjects decreased in body
weight, and the thylakoid group decreased significantly
more in body weight and in blood-lipid levels. More de-
tails describing the human trial, and the results can be
found in the previous study [12].
In this study only 34 out of the original 36 women
were included, due to incompliance in handing in faecal
samples. The experiment was conducted according to
the guidelines laid down in the Declaration of Helsinki
and all procedures involving human subjects were ap-
proved by the Ethics Committee of Lund University (no.
2006/361). Written and verbal informed consent was ob-
tained from all participants before the start of the
experiment.
The faecal samples were collected by the participants
in their home environment within two days before arriv-
ing at the clinic and put in −20 °C directly after collec-
tion. The participants had received sterile 50 ml tubes
with a small spoon attached in the lid, specially designed
for the purpose. At the clinic, the collected samples were
thawed and divided in two; one part was kept in −80 °C
until bacterial analyses were made and the other part
was put in an open glass container and left to dry in
100 °C for 48 h before the analysis of fat-content was
performed.
Analysis of fat content
The dry faecal material (~100 mg) was placed in a pre-
weighed 4 ml glass vial and weighed. A magnetic bead
together with 2 ml of dichloromethane (DCM) (Chro-
masolv, Sigma-Aldrich, Stockholm, Sweden) was added.
The vial was caped and the mixture was stirred vigor-
ously for two hours. After the mixture had sedimented,
the clear DCM phase was removed and transferred into
a plastic syringe (10 ml), fitted with a polyethylene frit
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(20 μm, 10 ml, Biotage, Uppsala, Sweden) and a syringe
filter (1 μm, Acrodisc glass fiber, Pall, NY, USA). The or-
ganic filtrate was collected in a pre-weighed glass vessel.
To the vial containing the residue faeces, 2 ml more of
DCM was added and the mixture was stirred vigorously
for another two hours. The DCM phase was transferred
as described above. The extraction sequence was re-
peated one more time to achieve a total of three times.
When executing the last extraction, all the solid material
was transferred together with the DCM to the syringe.
To ensure that as much of the organic solvent as pos-
sible was filtered into the glass vessel, a plunger was
used to squeeze the solid material. The solvent was then
removed by evaporation in a vacuum centrifuge (HT-4
series II, Genevac Technologies, Suffolk, UK) and the
residue (fat content) was weighed. In this analysis one
sample from the thylakoid group had to be excluded due
to insufficient amount of faecal sample. The analysis
therefore includes 17 women in the thylakoid group and
16 women in the control group.
Analysis of microbiota
DNA-extraction DNA from faecal samples was isolated
and purified using EZ1 DNA Tissue Kit and the robot
machine EZ1 Advanced XL (Bacteria card; Qiagen, Hil-
den, Germany) as previously described [19]. To further
disrupt the bacterial cell walls, a step of bead beating for
45 min at 4 °C was added before extraction in the EZ1
Advanced XL. Extracted DNA was stored in 1x TE-
buffer at 4 °C until further analyses.
Quantitative real-time PCR
The total amount of bacterial 16S ribosomal RNA
(rRNA) genes and the amount of 16S rRNA genes of
bacteria belonging to the Clostridium coccoides group,
the Clostridium leptum subgroup, Lactobacillus, the
Bacteroides fragilis group, Enterobacteriaceae and Akker-
mansia muciniphila-like bacteria were estimated using
separate qPCR assays. For all assays, each reaction con-
tained 10 μl 2× Rotor-Gene SYBR Green PCR Master
Mix (Qiagen), 0.5 μmol/l of each primer (Table 1), 2 μl
of template DNA (extracted as above, 200 ng feaces per
2 μl) and RNAse-free water to the final volume of 20 μl.
Samples, standards, and non-template controls were run
in triplicate. The thermal cycling was carried out in
Rotor-Gene Q (Qiagen) with a programme of 95 °C
for 5 min, followed by 40 cycles with denaturation at
95 °C for 5 s, annealing and elongation at 60 °C for
10–30 s. The fluorescent products were detected at
the last step of each cycle and melting curve analysis
was carried out to ensure specific amplification. Abso-
lute abundance of 16S rRNA genes was calculated
based on standard curves using Rotor-Gene Q Series
Software 2.1.0 (Qiagen, R2 > 0.996). Detection limit
were 102 genes/reaction for the C. leptum group,
Lactobacillus, the B. fragilis group, Enterobacteriaceae
and A. muciniphila-like bacteria. Total bacteria and
the Clostridium coccoides group were detected at 103
16S rRNA gene copies/reaction. As standard curves,
cloned PCR products from C. coccoides DSM935, C.
leptum DSM753, Lactobacillus plantarum DSM9843,
B. fragilis CCUG4856T, Escherichia coli CCUG29300T
and A. muciniphila (a clone confirmed by sequencing)
were used. Tenfold dilution series of the target DNA
were made in EB buffer (Qiagen). Number of bacteria
was expressed as numbers of 16S rRNA gene copies/
gram wet weight of faeces.
Thylakoids
The thylakoids (Appethyl®) used in the studies were pro-
vided by Greenleaf Medical AB (Stockholm, Sweden).
The extraction of thylakoids, in this case from spinach
leaves, has been described previously [9], with the differ-
ence that this powder was obtained after drumdrying.
Thylakoids can however be obtained from all green
leaves. 100 g of thylakoid-powder contain 41.7 g carbo-
hydrate (of which 38.7 g insoluble fibre), 23.5 g protein
and 11.9 g fat.
Biochemical analyses
The plasma concentration of CCK was measured only in
the acute rat study, in the blood-samples taken 30 min
after the orogastric bolus dose of Evans blue. CCK was
measured using RIA with a highly specific antiserum
(92128, detection limit 0.1 pmol/L) according to a previ-
ously described method [20].
Statistical analyses
Statistical data analyses were done using Prism, version
6 (GraphPad software Inc., San Diego, CA, USA). Con-
cerning the rat-experiments, data was controlled for nor-
mality using Shapiro-Wilk and KS normality tests, and
passed normality for all cases except the acute percent-
age of Evans migration. Therefore, the Mann Whitney t-
test was used for this calculation specifically, whereas
the Students t-test was used for the remaining calcula-
tions concerning the rat experiment. Also the descriptive
data for the human subjects and the amount of faecal fat
content passed normality calculations, and the statistical
differences were evaluated with paired Students t-test
within each treatment group. For the microbiota, statis-
tical evaluations were performed using the non-
parametric repeated measures Wilcoxon’s test. A value
of P ≤ 0.05 was considered significantly different.
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Results
The effect of thylakoids on gastric emptying and
intestinal transit
Rats treated with thylakoids, both acutely and given as a
food supplement for two weeks showed decreased gas-
tric emptying and intestinal transit time, as compared to
the control rats (Fig. 1a-b (GE)). The gastric emptying
was decreased by 41 % in the acute thylakoid experiment
(P = 0.02), and by 34 % in the two-week thylakoid sup-
plementation study (P = 0.08, not significant), compared
to the control conditions.
The intestinal transit, measured as the distance the
Evans blue had migrated down the intestinal tract during
30 min, was also decreased by thylakoid supplementa-
tion, however not significantly (Fig. 1 c-d (Mi)). The mi-
gration was decreased after thylakoid supplementation
both in the acute thylakoid experiment (P = 0.08) and
after the two-week thylakoid supplementation study
(P = 0.05). Thylakoid supplementation had no effect
on plasma concentration of CCK (P = 0.62) after the
bolus doses given in the acute study (Fig. 2). Plasma
concentrations were not measured in the two-week
diet-supplementation study, since CCK is released in
response to nutrients, and in this study we did not
control when the rats consumed their food.
Gastrointestinal effects of daily thylakoid
supplementation for three months
The fat content in the human faecal samples did not
change from before the diet intervention, in either thyla-
koid or control groups (Fig. 3). The addition of thyla-
koids did however affect the amount and composition of
the gut microbial flora. The quantification of bacteria in
the human faecal samples showed a significant increase
in the total number of 16S rRNA gene copies after con-
suming thylakoids for three months compared to before
the intervention (P = 0.03). In addition, in the thylakoid
group the amount of 16S rRNA genes specific for the B.
fragilis group was significantly higher after (P = 0.002),
compared to before the intervention, while no significant
differences were found for the control group (Table 2).
No significant differences were found in either thylakoid
or control groups regarding number of 16S rRNA gene
copies of A. muciniphilia-like bacteria, C. coccoides
group, C. leptum subgroup, Enterobacteriaceae or Lacto-
bacillus at endpoint compared to baseline (Table 2).
Discussion
The present study demonstrates that adding thylakoids
to the diet decreases gastric emptying and the intestinal
transit time, as well as show minor effects on the
amount and composition of the gut microbiota. More-
over, the faecal fat content was not affected by thylakoid
supplementation for three months.
The decreased gastric emptying and intestinal transit
time, however not significant, both in the acute
thylakoid-supplementation study and after two weeks of
daily thylakoid-intake corroborate previous results of de-
creased hunger, subjective and objective, obtained after
thylakoid supplementation in both animals and humans
[9–16, 21, 22]. We have previously shown that thylakoid
supplementation to the diet promotes the release of
satiety-hormones such as GLP-1 and CCK, and de-
creases the concentration of the hunger hormone
ghrelin [10–12, 15, 16, 23], all of which can be con-
nected to a reduced gastric emptying and decreased
Table 1 Information about the primers used for determination of 16S rRNA genes by qPCR
Target bacterial group Primer Sequence (5′-3′) Amplicon size (bp) Annealing and
elongation time (s)
Reference
Total bacteria F-tot GCA GGC CTA ACA CAT GCA AGT C 292 15 [39]
R-tot CTG CTG CCT CCC GTA GGA GT
Akkermansia muciniphilia-like bacteria AM1-F CAG CAC GTG AAG GTG GGG AC 327 20 [40]
AM2-R CCT TGC GGT TGG CTT CAG AT
Bacteroides fragilis group Bfra-F ATA GCC TTT CGA AAG RAA GAT 495 30 [41]
Bfra-R CCA GTA TCA ACT GCA ATT TTA
Clostridium coccoides group CcocF AAA TGA CGG TAC CTG ACT AA 440 20 [41]
CcocR CTT TGA GTT TCA TTC TTG CGA A
Clostridium leptum subgroup CleptF GCA CAA GCA GTG GAG T 239 20 [42]
CleptR3 CTT CCT CCG TTT TGT CAA
Enterobacteriaecae Eco1457-F CAT TGA CGT TAC CCG CAG AAG AAG C 195 10 [43]
Eco1652-R CTC TAC GAG ACT CAA GCT TGC
Lactobacillus Lact-F AGC AGT AGG GAA TCT TCC A 341 20 [44]
Lact-R CAC CGC TAC ACA TGG AG [45]
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intestinal motility. The levels of CCK in the acute study
with bolus feeding were not significantly different between
the thylakoid and control rats, even though all thylakoid
treated rats had slightly increased CCK plasma-
concentrations, as compared to the control rats (Fig. 3a). If
blood-samples had been taken at more than one time point
following the bolus feeding of thylakoid HFD versus control
HFD, there would have been better chances of finding sig-
nificant differences regarding plasma-concentration of
CCK. In the two-week supplementation study CCK was
not measured since the rats had ad libitum access to food,
and CCK is secreted postprandially in response to nutrients
present in the intestines [24–26]. Any effects that could
have been obtained by measuring CCK would therefore be
blunted by the voluntary food intake. In the future, it would
be interesting to control food intake in a long-time study to
be able to analyse levels of CCK as well as other appetite
regulating hormones such as ghrelin, GLP-1 and PYY, and
to do this continuously, not as a one-time measurement.
Intake of thylakoids for a longer time period have pre-
viously been shown to decrease body weight in humans
[12], as well as decrease body weight gain and amount
of body fat mass in rodents [9, 10]. Thylakoids have also
been found to affect subjective ratings of wanting and
liking for food, as well as ratings of hunger, satiety and
cravings for palatable food [12–15, 23], all of which can
be explained by effects on the appetite-regulating
hormones mentioned above. The physiological effect de-
scribed here of a reduced gastric emptying, together with
Fig. 1 a-d Decreased gastric emptying (Fig. a-b (GE), % of total dose of Evans blue) after thylakoid supplementation, both in the acute study
where thylakoids in HFD was given as a bolus dose (a, control n = 6, thylakoid n = 8) and after two weeks intake of thylakoids in HFD (b, control
n = 7, thylakoid n = 7). Decreased small intestinal motility, measured as the distance of Evans blue migration (Fig. c-d (Mi), % of total length), both
in the acute study where thylakoids in HFD was given as a bolus dose (c, control n = 6, thylakoid n = 8) and after two weeks intake of thylakoids
in HFD (d, control n = 7, thylakoid n = 7). Bars represent mean + SEM. Statistical P-levels of ≤0.05 was considered to be significant (* = P < 0.05)
Fig. 2 Effect on plasma-concentration of CCK 60 min after a bolus dose
of thylakoid supplemented HFD vs. control HFD (control n= 6, thylakoid
n= 8 rats). Bars represent mean + SEM. No statistical difference between
thylakoid and control-treated rats was observed
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an increased secretion of hormones such as GLP-1 and
CCK, would result in an increased feeling of satiety. This
could in turn decrease food intake and thereby promote
body weight loss [27–29]. The present study showing a
decreased gastric emptying and intestinal transit after
thylakoid supplementation, however not in a significant
manner, brings a novel mechanistic explanation to the
results obtained previously in the thylakoid-appetite re-
search area.
The human faecal samples collected before and after
thylakoid or control dietary supplementation for three
months, showed that thylakoid-supplementation has no
influence on the total intestinal absorption of dietary
lipids. Since thylakoids have an affinity for both the
lipase/co-lipase complex and to triglycerides [7, 30], it
has been discussed whether thylakoids could have the
same gastrointestinal side-effects, such as steatorrhea, as
have been shown after orlistat-treatment [5]. The
amount of faecal fat has previously been shown not to
be affected in rats treated with a HFD with or without
thylakoid supplementation for 10 days [22]. The present
study is however the first study studying faecal fat con-
tent after long-term intake of thylakoids in humans. The
results of this study, showing no differences in the
amount of faecal fat between thylakoid and control,
confirms the results from previous studies showing that
thylakoids inhibit lipase activity in a reversible fashion
[7, 22, 30, 31]. Consequently, we can with certainty say
that thylakoid treatment does not cause GI side-effects
such as steatorrhea, which are common for other lipase
inhibitors [5].
The altered gut microbial composition, however
minor, found in the present study, has previously also
been showed in a study performed in rats [22]. The gut
microbiota has been proposed to be partly responsible
for the secretion of appetite regulating hormones such
as GLP-1 and PYY [2, 32], since these hormones are se-
creted from intestinal enterocytes. The gut microbiota
also promotes the production of SCFA, which have been
proposed to have effects on lipid, glucose and choles-
terol metabolism in the host [33, 34]. Indeed, a recent
study in rats fed a high-fat diet with or without thyla-
koids demonstrated that thylakoid supplementation re-
sulted in a reduced respiratory quotient (RQ), indicative
of increased fatty acid oxidation [35]. This may have
been caused by altered gut microbiota. The oxidation of
fatty acids has been found to be increased by SCFA,
while the synthesis of lipids is decreased [34]. The re-
sults are decreased concentrations of blood lipids and
reduced accumulation of lipids, improved glucose and
Table 2 Concentrations of specific bacterial groups, detected by qPCR, in faeces of volunteers consuming the thylakoid supplement
for 3 months compared to volunteers consuming the control supplement. Wilcoxon’s test was used to estimate statistical
differences. Medians and interquartile ranges are reported
Bacterial taxa Control Control P Thylakoid Thylakoid P
Before intervention After three months Before intervention After three months
Log 16S rRNA gene
copies/g faeces
Log 16S rRNA gene
copies/g faeces
Log 16S rRNA gene
copies/g faeces
Log 16S rRNA gene
copies/g faeces
Median Range Median Range Median Range Median Range
Total bacteria 11.0 10.8–11.2 10.8 10.6–11.0 0.464 10.9 10.8–11.1 11.2 11.0–11.4 0.034
Akkermansia muciniphila-like 8.7 7.8–10.2 9.1 7.7–9.6 0.850 9.9 8.8–10.5 9.6 8.9–10.3 0.744
Bacteroides fragilis group 8.7 8.3–9.2 9.2 8.4–9.2 0.252 9.1 8.8–9.6 9.5 9.2–9.9 0.002
Clostridium coccoides group 10.3 10.2–10.9 10.2 10.0–10.5 0.298 10.5 10.4–10.9 10.8 10.3–11.0 0.325
Clostridium leptum subgroup 10.5 10.0–10.6 10.4 9.6–10.6 0.298 10.6 10.1–10.8 10.6 10.3–10.8 0.865
Enterobacteriaceae 8.3 7.4–9.0 8.2 6.3–8.7 0.495 7.4 6.6–8.3 7.5 7.0–8.8 0.393
Lactobacillus 7.1 6.6–8.5 7.5 6.6–8.3 0.636 7.4 6.8–7.8 7.6 7.0–7.9 0.455
Significant p-values are highlighted in bold and italicized
Fig. 3 Fat-content in the faecal samples obtained from the overweight
women before and after the three-month dietary supplementation
period with thylakoids (n= 17) or placebo (n= 16). No significant
difference between before and after the study was found in any of the
groups. Bars represent mean + SEM
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insulin homeostasis, as well as positive effects on the
body-weight regulation due to increased secretion of ap-
petite regulating hormones such as GLP-1 and decreased
food intake [32, 34, 36–38]. The previous results from
thylakoid supplementation in both human and animal
interventional studies could thereby, at least partly, be a
consequence of an altered gut microbiota. However, this
needs to be further elucidated in future studies, includ-
ing a larger population and a longer study-time. In fu-
ture studies also the amount of SCFA should be
measured, as this is a limitation in the present study.
During the three-month human intervention previ-
ously published in Appetite, all subjects reduced their
body-weight. However, the present study includes only
34 women out of the original 36 enrolled in the pre-
viously study [12]. The differences found in gut
microbiota between thylakoid and control group could
thereby be caused by body-weight changes, but since
the previous study also showed changes in appetite-
regulating hormones, we propose it is the other way
around, since a change in the gut microbiota have
been shown to result in increased secretion of SCFA,
PYY and GLP-1, due to colonic fermentation [2, 32].
Previous studies describing the effects of thylakoids
have shown decreased amount of cholesterol, in-
creased secretion of satiety hormones, and significant
weight-loss [12, 13]. Thereby we propose that also the
gut microbiota corroborates in the mechanistic expla-
nations for these results.
Conclusion
In conclusion, the present study describes a decreased
gastric emptying and intestinal transit time after intake
of thylakoids in rats. Even though all results are not
significantly proven, the results add to the mechanistic
explanation to the earlier observed changes in appetite-
regulating hormones after thylakoid intake. Whether the
delayed gastric emptying is a cause or consequence of
the decreased levels of peptides affecting hunger, and el-
evated levels of peptides affecting satiety and reward in
previous studies, remains unanswered. Moreover, the re-
sults show that thylakoid consumption does not cause
steatorrhea, and that thylakoid intake promotes a minor
change in the gut microbiota. The minor change in mi-
crobial composition may be caused by weight-loss, but
we propose that the weight-loss is the consequence of
the change in microflora combined with the change in
appetite-regulating hormones as has been shown in earl-
ier studies. Together with previous effects of thylakoid
consumption, we propose thylakoids as a promising nat-
ural supplement for weight-management, without any
known side effects, acting to affect the digestion, metab-
olism and leading to healthy eating habits.
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